Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: allosteric modulators - Addex Therapeutics

X
Drug Profile

Research programme: allosteric modulators - Addex Therapeutics

Alternative Names: A2A PAM; ADX 68692; ADX-71743; ADX-71943; ADX-92639; Cpd 23; FSH NAM; FSHR/LHR NAM for sex hormone dependent tumours and reproductive system disorders - Addex Therapeutics; GABA-BR PAM for overactive bladder - Addex; GABABPAMs; IL1R1 NAM (CD121a); mGlu2 NAM; mGlu3 PAM; mGlu4 PAM; mGlu7 NAM; mGluR2 NAM; mGluR3 NAM; mGluR3 PAM; mGluR7 NAM; Orexin 2R NAM; TNFR1 NAM (CD120a); TNFR1 NAM (TNF receptor superfamily); TrkB PAM (RTK superfamily) - Addex Therapeutics; TrkB receptor agonists - Addex; TrkB receptor modulators - Addex; TrkBPAM

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Pharmaceuticals; Addex Therapeutics
  • Class Analgesics; Anti-inflammatories; Antidementias; Antidepressants; Antigouts; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Neuroprotectants; Neuropsychotherapeutics; Nootropics; Osteoporosis therapies; Sleep disorder therapies; Small molecules; Urologics
  • Mechanism of Action Adenosine A2 receptor modulators; Chorionic gonadotropin modulators; Follicle stimulating hormone modulators; GABA B receptor agonists; Interleukin 2 receptor modulators; Luteinising hormone modulators; Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 7 modulators; Metabotropic glutamate receptor modulators; Orexin receptor type 2 modulators; Ovarian follicle modulators; TrkB receptor agonists; TrkB receptor modulators; Tumour necrosis factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Charcot-Marie-Tooth disease; Cognition disorders; Endometriosis; Fragile X syndrome; Huntington's disease; Major depressive disorder; Neurodegenerative disorders; Pain; Parkinson's disease; Polycystic ovary syndrome; Post-traumatic stress disorders; Substance-related disorders; Urinary incontinence; Visceral pain
  • Discontinued Gastro-oesophageal reflux; Gout; Inflammatory bowel diseases; Osteoarthritis; Osteoporosis; Pregnancy; Prostate cancer; Psoriasis; Rheumatoid arthritis; Sleep disorders

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland (PO)
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Germany (PO)
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Netherlands (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top